It’s been a crucial week for SCYNEXIS, Inc. (NASDAQ:SCYX); here’s what analysts have to say.

April 11, 2018 - By Marie Mckinney

Investors sentiment increased to 1.43 in 2017 Q4. Its up 0.34, from 1.09 in 2017Q3. It improved, as 4 investors sold SCYNEXIS, Inc. shares while 3 reduced holdings. 4 funds opened positions while 6 raised stakes. 8.53 million shares or 0.18% less from 8.55 million shares in 2017Q3 were reported.
Virtu Financial Limited Liability Corp holds 24,183 shares or 0% of its portfolio. Susquehanna Gp Limited Liability Partnership owns 95,163 shares for 0% of their portfolio. Granite Point Cap Mngmt Limited Partnership invested in 141,750 shares. Rbf Capital holds 0% or 11,100 shares in its portfolio. Iguana Ltd Liability, a New York-based fund reported 250,000 shares. Rock Springs Capital Ltd Partnership holds 760,000 shares or 0.08% of its portfolio. Us Retail Bank De has 0% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 31,500 shares. Federated Invsts Inc Pa holds 4.21M shares or 0.03% of its portfolio. Creative Planning invested in 47,300 shares. Fny Managed Accounts Ltd Liability Co holds 0% or 500 shares. Dimensional Fund Advsr L P reported 245,580 shares. National Asset Management has invested 0.09% in SCYNEXIS, Inc. (NASDAQ:SCYX). Geode Capital Management Limited Liability holds 0% or 128,724 shares in its portfolio. Royal Bancorp Of Canada invested 0% in SCYNEXIS, Inc. (NASDAQ:SCYX). Blackrock accumulated 104,339 shares or 0% of the stock.

Since March 8, 2018, it had 7 insider buys, and 0 sales for $246,885 activity. Another trade for 2,959 shares valued at $5,001 was bought by Sukenick Scott. 6,000 shares valued at $8,160 were bought by Angulo Gonzalez David on Thursday, March 29. Taglietti Marco bought $169,000 worth of stock or 100,000 shares. HASTINGS DAVID C bought 11,834 shares worth $19,999.

SCYNEXIS, Inc. (NASDAQ:SCYX) Ratings Coverage

Among 2 analysts covering SCYNEXIS (NASDAQ:SCYX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SCYNEXIS had 2 analyst reports since October 24, 2017 according to SRatingsIntel. Below is a list of SCYNEXIS, Inc. (NASDAQ:SCYX) latest ratings and price target changes.

10/04/2018 Broker: Seaport Global Rating: Buy New Target: $4 Initiates Coverage On
24/10/2017 Broker: Guggenheim Rating: Buy New Target: $6 Initiates Coverage On

The stock increased 1.60% or $0.02 during the last trading session, reaching $1.27. About 707,755 shares traded or 80.60% up from the average. SCYNEXIS, Inc. (NASDAQ:SCYX) has declined 51.26% since April 11, 2017 and is downtrending. It has underperformed by 62.81% the S&P500.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $59.48 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

SCYNEXIS, Inc. (NASDAQ:SCYX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.